|
1）日本循環器学会．循環器病の診断と治療に関するガイドライン（2009年度合同研究班報告）．慢性心不全治療ガイドライン（2010年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
|
|
|
|
|
2）Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772-6
|
|
|
|
|
3）Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75
|
|
|
|
|
|
4）Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-7
|
|
|
|
|
|
5）McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100: 1056-64
|
|
|
|
|
|
6）Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-906
|
|
|
|
|
|
7）Sudoh T, Minamino N, T, et al. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168: 863-70
|
|
|
|
|
|
8）Mukoyama M, Nakao K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402-12
|
|
|
|
|
|
9）Kitakaze M, Asakura M, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370: 1483-93
|
|
|
|
|
|
10）Colucci WS, Elkayam U, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated heart failure. N Engl J Med. 2000; 343: 246-53
|
|
|
|
|
|
11）Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990; 323: 757-8
|
|
|
|
|
|
12）Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993; 88: 82-91
|
|
|
|
|
|
13）Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90: 195-203
|
|
|
|
|
|
14）Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003; 107: 2786-92
|
|
|
|
|
|
15）Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation. 2004; 110: 1387-91
|
|
|
|
|
|
16）Inoue T, Kawai M, Nakane T, et al. Influence of low-grade inflammation on plasma B-type natriuretic peptide levels. Intern Med. 2010; 49: 2659-68
|
|
|
|
|
17）Nakane T, Kawai M, Komukai K, et al. Contribution of extracardiac factors to the inconsistency between plasma B-type natriuretic peptide levels and the severity of pulmonary congestion on chest X-rays in the diagnosis of heart failure. Intern Med. 2012; 51: 239-48
|
|
|
|
|
|
18）Waeber B, Feihl F. Blood-pressure reduction with LCZ696. Lancet. 2010; 375: 1228-9
|
|
|
|
|
|
19）Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000; 356: 615-20
|
|
|
|
|
|
20）Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002; 106: 920-6
|
|
|
|
|
|
21）Solomon SD, Zile M, Pieske B, et al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380: 1387-95
|
|
|
|
|
|
22）Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010; 50: 401-14
|
|
|
|
|
|
23）Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375: 1255-66
|
|
|
|
|